Cited 54 times in
PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박성윤 | - |
dc.contributor.author | 서지원 | - |
dc.contributor.author | 신수진 | - |
dc.contributor.author | 오영택 | - |
dc.contributor.author | 정대철 | - |
dc.contributor.author | 조남훈 | - |
dc.contributor.author | 최영득 | - |
dc.date.accessioned | 2018-07-20T07:49:00Z | - |
dc.date.available | 2018-07-20T07:49:00Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0361-803X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160551 | - |
dc.description.abstract | OBJECTIVE: The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS: A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS: Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION: PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springfield, Ill., Thomas | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF ROENTGENOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Biopsy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Magnetic Resonance Imaging/methods* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Grading | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prostate-Specific Antigen/blood | - |
dc.subject.MESH | Prostatectomy | - |
dc.subject.MESH | Prostatic Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Prostatic Neoplasms/pathology* | - |
dc.subject.MESH | Prostatic Neoplasms/surgery | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sensitivity and Specificity | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Radiology | - |
dc.contributor.googleauthor | Ji Won Seo | - |
dc.contributor.googleauthor | Su-Jin Shin | - |
dc.contributor.googleauthor | Young Taik Oh | - |
dc.contributor.googleauthor | Dae Chul Jung | - |
dc.contributor.googleauthor | Nam Hoon Cho | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Sung Yoon Park | - |
dc.identifier.doi | 10.2214/AJR.16.16981 | - |
dc.contributor.localId | A01509 | - |
dc.contributor.localId | A04585 | - |
dc.contributor.localId | A04596 | - |
dc.contributor.localId | A02390 | - |
dc.contributor.localId | A03592 | - |
dc.contributor.localId | A03812 | - |
dc.contributor.localId | A04111 | - |
dc.relation.journalcode | J00116 | - |
dc.identifier.eissn | 1546-3141 | - |
dc.identifier.pmid | 28418690 | - |
dc.identifier.url | https://www.ajronline.org/doi/abs/10.2214/AJR.16.16981 | - |
dc.subject.keyword | Gleason score | - |
dc.subject.keyword | MRI | - |
dc.subject.keyword | PI-RADS | - |
dc.subject.keyword | clinically significant cancer | - |
dc.subject.keyword | prostate cancer | - |
dc.contributor.alternativeName | Park, Sung Yoon | - |
dc.contributor.alternativeName | Seo, Ji Won | - |
dc.contributor.alternativeName | Shin, Su Jin | - |
dc.contributor.alternativeName | Oh, Young Taik | - |
dc.contributor.alternativeName | Jung, Dae Chul | - |
dc.contributor.alternativeName | Cho, Nam Hoon | - |
dc.contributor.alternativeName | Choi, Young Deuk | - |
dc.contributor.affiliatedAuthor | Park, Sung Yoon | - |
dc.contributor.affiliatedAuthor | Seo, Ji Won | - |
dc.contributor.affiliatedAuthor | Shin, Su Jin | - |
dc.contributor.affiliatedAuthor | Oh, Young Taik | - |
dc.contributor.affiliatedAuthor | Jung, Dae Chul | - |
dc.contributor.affiliatedAuthor | Cho, Nam Hoon | - |
dc.contributor.affiliatedAuthor | Choi, Young Deuk | - |
dc.citation.volume | 209 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | W1 | - |
dc.citation.endPage | W9 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF ROENTGENOLOGY, Vol.209(1) : W1-W9, 2017 | - |
dc.identifier.rimsid | 44786 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.